Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using 211At-CXCR4 monoclonal antibody

Abstract To explore stem-cell-targeted radioimmunotherapy with α-particles in acute myelogenous leukemia (AML), pharmacokinetics and dosimetry of the 211 At-labeled anti-C-X-C chemokine receptor type 4 monoclonal antibody ( 211 At-CXCR4 mAb) were conducted using tumor xenografted mice. The biologica...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2020-04, Vol.10 (1), p.6810, Article 6810
Main Authors: Oriuchi, Noboru, Aoki, Miho, Ukon, Naoyuki, Washiyama, Kohshin, Tan, Chengbo, Shimoyama, Saki, Nishijima, Ken-ichi, Takahashi, Kazuhiro, Ito, Hiroshi, Ikezoe, Takayuki, Zhao, Songji
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
Bone marrow
Chemokines
CXCR4 protein
Dosimetry
Half-life
Kidneys
Leukemia
Monoclonal antibodies
Myeloid leukemia
Pharmacokinetics
Stem cells
Xenografts
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract To explore stem-cell-targeted radioimmunotherapy with α-particles in acute myelogenous leukemia (AML), pharmacokinetics and dosimetry of the 211 At-labeled anti-C-X-C chemokine receptor type 4 monoclonal antibody ( 211 At-CXCR4 mAb) were conducted using tumor xenografted mice. The biological half-life of 211 At-CXCR4 mAb in blood was 15.0 h. The highest tumor uptake of 5.05%ID/g with the highest tumor-to-muscle ratio of 8.51 ± 6.14 was obtained at 6 h. Radiation dosimetry estimated with a human phantom showed absorbed doses of 0.512 mGy/MBq in the bone marrow, 0.287 mGy/MBq in the kidney, and
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-020-63557-9